NASDAQ:STRO Sutro Biopharma (STRO) Stock Forecast, Price & News $4.50 +0.01 (+0.22%) (As of 11:57 AM ET) Add Compare Share Share Today's Range$4.34▼$4.5350-Day Range$4.25▼$5.8852-Week Range$3.33▼$8.72Volume84,433 shsAverage Volume482,007 shsMarket Capitalization$270.86 millionP/E RatioN/ADividend YieldN/APrice Target$17.33 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial MediaSustainabilityProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial MediaSustainability Sutro Biopharma MarketRank™ ForecastAnalyst RatingModerate Buy2.83 Rating ScoreUpside/Downside285.2% Upside$17.33 Price TargetShort InterestBearish5.15% of Shares Sold ShortDividend StrengthN/ASustainability-0.70Upright™ Environmental ScoreNews Sentiment0.22Based on 2 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($2.87) to ($2.53) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.06 out of 5 starsMedical Sector1027th out of 1,980 stocksBiological Products, Except Diagnostic Industry159th out of 330 stocks 3.4 Analyst's Opinion Consensus RatingSutro Biopharma has received a consensus rating of Buy. The company's average rating score is 2.83, and is based on 5 buy ratings, 1 hold rating, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $17.33, Sutro Biopharma has a forecasted upside of 285.2% from its current price of $4.50.Amount of Analyst CoverageSutro Biopharma has only been the subject of 4 research reports in the past 90 days. Previous Next 1.0 Short Interest Percentage of Shares Shorted5.15% of the outstanding shares of Sutro Biopharma have been sold short.Short Interest Ratio / Days to CoverSutro Biopharma has a short interest ratio ("days to cover") of 6.6.Change versus previous monthShort interest in Sutro Biopharma has recently increased by 4.38%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldSutro Biopharma does not currently pay a dividend.Dividend GrowthSutro Biopharma does not have a long track record of dividend growth. Previous Next 4.7 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreSutro Biopharma has received a 73.67% net impact score from Upright. The largest positive contribution comes from its "Creating knowledge" impact, which is driven by its "Preclinical research services for physical health" and "Clinical research services for physical health" products. See details.Environmental SustainabilityThe Environmental Impact score for Sutro Biopharma is -0.70. Previous Next 1.8 News and Social Media Coverage News SentimentSutro Biopharma has a news sentiment score of 0.22. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.63 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Sutro Biopharma this week, compared to 2 articles on an average week.Search Interest2 people have searched for STRO on MarketBeat in the last 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Sutro Biopharma insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 7.40% of the stock of Sutro Biopharma is held by insiders.Percentage Held by Institutions87.64% of the stock of Sutro Biopharma is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Sutro Biopharma are expected to grow in the coming year, from ($2.87) to ($2.53) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Sutro Biopharma is -1.89, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Sutro Biopharma is -1.89, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioSutro Biopharma has a P/B Ratio of 1.46. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Sutro Biopharma (NASDAQ:STRO) StockSutro Biopharma Inc. engages in the drug discovery, development and manufacture of pharmaceutical products. It focuses on the next generation cancer and autoimmune therapeutics. The company was founded by James R. Swartz and Sutanto Widjaja on April 21, 2003 and is headquartered in South San Francisco, CA.Read More Receive STRO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Sutro Biopharma and its competitors with MarketBeat's FREE daily newsletter. Email Address STRO Stock News HeadlinesMay 31, 2023 | finance.yahoo.comSutro Biopharma to Participate in the Jefferies Healthcare ConferenceMay 28, 2023 | finance.yahoo.comInvestors in Sutro Biopharma (NASDAQ:STRO) have unfortunately lost 51% over the last three yearsJune 1, 2023 | Edge On The Street (Ad)AI Getting Close to Thinking Like HumansTechnology experts working with neuroscientists have created the world's first Artificial Intelligence Network Operating System. AI can now process information like the human brain and understand the world the way humans do.May 25, 2023 | americanbankingnews.comSutro Biopharma, Inc. (NASDAQ:STRO) Receives $17.33 Consensus Price Target from AnalystsMay 20, 2023 | americanbankingnews.comSutro Biopharma, Inc. (NASDAQ:STRO) Expected to Post Q2 2023 Earnings of ($0.73) Per ShareMay 17, 2023 | msn.comJMP Securities Reiterates Sutro Biopharma (STRO) Market Outperform RecommendationMay 17, 2023 | americanbankingnews.comQ2 2023 EPS Estimates for Sutro Biopharma, Inc. Lowered by Analyst (NASDAQ:STRO)May 16, 2023 | benzinga.comSutro Biopharma Stock (NASDAQ:STRO), Insider Trading ActivityJune 1, 2023 | Edge On The Street (Ad)Graphite versus Lithium - What Investors Should KnowOver 18 million EVs will be cruising U.S roads by 2030. And every one million EVs manufactured will require 82,000 tons of the metal graphite for their batteries. That's a total of 1,476,000 tons of graphite! Graphite is actually the largest component of EV batteries - NOT lithium. Experts warn of a massive graphite shortfall, especially since North America currently has no operating graphite mines.May 16, 2023 | msn.comHC Wainwright & Co. Reiterates Sutro Biopharma (STRO) Buy RecommendationMay 15, 2023 | finance.yahoo.comSutro Biopharma Reports First Quarter 2023 Financial Results, Business Highlights and Select Anticipated MilestonesMay 4, 2023 | finance.yahoo.comSutro Biopharma, Inc. (STRO) Soars 11.3%: Is Further Upside Left in the Stock?May 3, 2023 | msn.comSutro, Mersana jump after Immunogen data for ovarian cancer therapyMay 1, 2023 | finance.yahoo.comSutro Biopharma, Inc. (STRO) May Report Negative Earnings: Know the Trend Ahead of Q1 ReleaseApril 30, 2023 | americanbankingnews.comSutro Biopharma, Inc. (NASDAQ:STRO) Given Average Rating of "Moderate Buy" by AnalystsApril 27, 2023 | finance.yahoo.comSutro Biopharma Announces the Departure of President of Research & Chief Scientific OfficerApril 18, 2023 | finance.yahoo.comSutro Biopharma Presents Preclinical Data for its ROR1 Targeting Antibody Drug Conjugate STRO-003 at the AACR Annual Meeting 2023April 17, 2023 | finance.yahoo.comInvestors Don't See Light At End Of Sutro Biopharma, Inc.'s (NASDAQ:STRO) TunnelApril 12, 2023 | americanbankingnews.comCoherus BioSciences (NASDAQ:CHRS) versus Sutro Biopharma (NASDAQ:STRO) Head to Head ReviewApril 5, 2023 | americanbankingnews.comSutro Biopharma, Inc. (NASDAQ:STRO) Receives Average Rating of "Moderate Buy" from BrokeragesApril 3, 2023 | markets.businessinsider.comJMP Securities Reaffirms Their Buy Rating on Sutro Biopharma (STRO)April 3, 2023 | americanbankingnews.comSutro Biopharma (NASDAQ:STRO) Price Target Cut to $17.00 by Analysts at JMP SecuritiesApril 1, 2023 | americanbankingnews.comSutro Biopharma (NASDAQ:STRO) Price Target Lowered to $16.00 at HC WainwrightApril 1, 2023 | americanbankingnews.comSutro Biopharma (NASDAQ:STRO) Receives "Outperform" Rating from WedbushApril 1, 2023 | seekingalpha.comSTRO Sutro Biopharma, Inc.March 31, 2023 | markets.businessinsider.comWhere Sutro Biopharma Stands With AnalystsMarch 30, 2023 | finance.yahoo.comSutro Biopharma, Inc. (STRO) Reports Q4 Loss, Misses Revenue EstimatesSee More Headlines STRO Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart STRO Company Calendar Last Earnings11/10/2021Today6/01/2023Next Earnings (Estimated)8/14/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Biological products, except diagnostic Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:STRO CUSIPN/A CIK1382101 Webwww.sutrobio.com Phone(650) 392-8412FaxN/AEmployees224Year FoundedN/APrice Target and Rating Average Stock Price Forecast$17.33 High Stock Price Forecast$25.00 Low Stock Price Forecast$8.00 Forecasted Upside/Downside+286.0%Consensus RatingModerate Buy Rating Score (0-4)2.83 Research Coverage6 Analysts Profitability EPS (Most Recent Fiscal Year)($2.38) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-119,200,000.00 Net Margins-174.57% Pretax Margin-170.69% Return on Equity-59.26% Return on Assets-32.13% Debt Debt-to-Equity RatioN/A Current Ratio5.11 Quick Ratio5.11 Sales & Book Value Annual Sales$67.77 million Price / Sales3.99 Cash FlowN/A Price / Cash FlowN/A Book Value$3.08 per share Price / Book1.46Miscellaneous Outstanding Shares60,190,000Free Float55,738,000Market Cap$270.25 million OptionableNot Optionable Beta0.88 Key ExecutivesWilliam J. NewellPresident, Chief Executive Officer & DirectorEdward C. AlbiniChief Financial Officer & SecretaryTrevor HallamChief Scientific Officer & President-ResearchShabbir T. AnikChief Technical Operations OfficerCraig BermanVice President-Clinical DevelopmentKey CompetitorsFusion PharmaceuticalsNASDAQ:FUSNCabaletta BioNASDAQ:CABAProKidneyNASDAQ:PROKNanoString TechnologiesNASDAQ:NSTGCaribou BiosciencesNASDAQ:CRBUView All CompetitorsInstitutional OwnershipAmeriprise Financial Inc.Bought 47,462 shares on 5/22/2023Ownership: 0.215%Putnam Investments LLCBought 71,142 shares on 5/22/2023Ownership: 0.118%JPMorgan Chase & Co.Sold 116,109 shares on 5/18/2023Ownership: 0.119%New York State Common Retirement FundSold 17,825 shares on 5/18/2023Ownership: 0.023%Susquehanna Fundamental Investments LLCSold 4,079 shares on 5/16/2023Ownership: 0.121%View All Institutional Transactions STRO Stock - Frequently Asked Questions Should I buy or sell Sutro Biopharma stock right now? 6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Sutro Biopharma in the last twelve months. There are currently 1 hold rating and 5 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" STRO shares. View STRO analyst ratings or view top-rated stocks. What is Sutro Biopharma's stock price forecast for 2023? 6 Wall Street analysts have issued twelve-month target prices for Sutro Biopharma's stock. Their STRO share price forecasts range from $8.00 to $25.00. On average, they anticipate the company's stock price to reach $17.33 in the next twelve months. This suggests a possible upside of 286.0% from the stock's current price. View analysts price targets for STRO or view top-rated stocks among Wall Street analysts. How have STRO shares performed in 2023? Sutro Biopharma's stock was trading at $8.08 at the start of the year. Since then, STRO shares have decreased by 44.4% and is now trading at $4.49. View the best growth stocks for 2023 here. When is Sutro Biopharma's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, August 14th 2023. View our STRO earnings forecast. How were Sutro Biopharma's earnings last quarter? Sutro Biopharma, Inc. (NASDAQ:STRO) issued its quarterly earnings data on Wednesday, November, 10th. The company reported ($0.67) EPS for the quarter, missing analysts' consensus estimates of ($0.65) by $0.02. The firm earned $8.52 million during the quarter, compared to analysts' expectations of $8.85 million. Sutro Biopharma had a negative trailing twelve-month return on equity of 59.26% and a negative net margin of 174.57%. What ETFs hold Sutro Biopharma's stock? ETFs with the largest weight of Sutro Biopharma (NASDAQ:STRO) stock in their portfolio include Simplify Propel Opportunities ETF (SURI), Invesco Nasdaq Future Gen 200 ETF (QQQS), SPDR S&P Biotech ETF (XBI), Direxion Daily S&P Biotech Bull 3x Shares (LABU), iShares Biotechnology ETF (IBB), What is William J. Newell's approval rating as Sutro Biopharma's CEO? 11 employees have rated Sutro Biopharma Chief Executive Officer William J. Newell on Glassdoor.com. William J. Newell has an approval rating of 100% among the company's employees. This puts William J. Newell in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. What other stocks do shareholders of Sutro Biopharma own? Based on aggregate information from My MarketBeat watchlists, some companies that other Sutro Biopharma investors own include Pfizer (PFE), VBI Vaccines (VBIV), Aldeyra Therapeutics (ALDX), Dynavax Technologies (DVAX), Fulcrum Therapeutics (FULC), IDEAYA Biosciences (IDYA), Provention Bio (PRVB), Sorrento Therapeutics (SRNE), Xeris Biopharma (XERS) and AbbVie (ABBV). When did Sutro Biopharma IPO? (STRO) raised $75 million in an IPO on Thursday, September 27th 2018. The company issued 5,000,000 shares at $14.00-$16.00 per share. Cowen and Piper Jaffray acted as the underwriters for the IPO and JMP Securities and Wedbush PacGrow were co-managers. What is Sutro Biopharma's stock symbol? Sutro Biopharma trades on the NASDAQ under the ticker symbol "STRO." Who are Sutro Biopharma's major shareholders? Sutro Biopharma's stock is owned by a number of institutional and retail investors. Top institutional investors include Suvretta Capital Management LLC (9.45%), BlackRock Inc. (8.34%), Rubric Capital Management LP (7.24%), State Street Corp (4.86%), Candriam S.C.A. (3.09%) and Dimensional Fund Advisors LP (1.95%). Insiders that own company stock include John Gordon Freund, Nicki Vasquez, Trevor Hallam and William J Newell. View institutional ownership trends. How do I buy shares of Sutro Biopharma? Shares of STRO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Sutro Biopharma's stock price today? One share of STRO stock can currently be purchased for approximately $4.49. How much money does Sutro Biopharma make? Sutro Biopharma (NASDAQ:STRO) has a market capitalization of $270.25 million and generates $67.77 million in revenue each year. The company earns $-119,200,000.00 in net income (profit) each year or ($2.38) on an earnings per share basis. How many employees does Sutro Biopharma have? The company employs 224 workers across the globe. How can I contact Sutro Biopharma? Sutro Biopharma's mailing address is 310 Utah Avenue Suite 150, South San Francisco CA, 94080. The official website for the company is www.sutrobio.com. The company can be reached via phone at (650) 392-8412 or via email at ajchang@sutrobio.com. This page (NASDAQ:STRO) was last updated on 6/1/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Sutro Biopharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.